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Abstract
Recently, two studies provided convincing evidence that IFN
regulatory factor 5 (IRF5) gene polymorphisms are significantly
associated with systemic lupus erythematosus (SLE) in several
white populations. To replicate the association with SLE in an
Asian population, we examined the genetic effects in our SLE
cohort from a Korean population. A total of 1,565 subjects,
composed of 593 cases and 972 controls, were genotyped
using the TaqMan® (Applied Biosystems, Foster City, CA, USA)
method. The genetic effects of polymorphisms on the risk of SLE
were evaluated using χ2 tests and a Mantel–Haenszel meta-
analysis. Statistical analysis revealed results in the Korean
population were similar to the previous reports from white
populations. The rs2004640 T allele had a higher frequency in
SLE cases (0.385) than controls (0.321; odds ratio (OR) =
1.32, P = 0.0003). In combined analysis, including all seven
independent cohorts from the three studies so far, robust and
consistent associations of the rs2004640 T allele with SLE
were observed. The estimate of risk was OR = 1.44 (range,
1.34–1.55), with an overall P = 1.85 × 10-23 for the rs2004640
T allele. The haplotype (rs2004640T–rs2280714T) involved in
both the alternative splice donor site and the elevated
expression of IRF5 also had a highly significant association with
SLE (pooled, P = 2.11 × 10-16). Our results indicate that the
genetic effect on the risk of SLE mediated by IRF5 variants can
be generally accepted in both white and Asian populations.
Introduction
Recently, two studies provided convincing evidence that IFN
regulatory factor 5 (IRF5 [MIM 607218]) gene polymorphisms
are significantly associated with systemic lupus erythemato-
sus (SLE [MIM 152700]). The studies included – seven inde-
pendent SLE cohorts from white populations (Sweden-1,
Finland, Iceland, USA, Spain, Sweden-2 and Argentina) and
involved both family-based and case-control cohorts [1,2]. In
both studies, the dbSNP rs2004640 (T > G) of IRF5 showed
strong associations with the risk of SLE, for example higher
frequencies in SLE cases than controls (combined analysis,
61% in SLE cases versus 51% in controls; P = 4.2 × 10-21).
Graham and colleagues, through further experiments in the
later study, also identified a common (frequency, 50.0% in
white populations) IRF5  haplotype that has both a splice
donor site, which allows expression of multiple IRF5 isoforms
containing exon 1B, and a separate genetic effect associated
with elevated levels of expression of IRF5 [1]. To replicate the
association with SLE in an Asian population, we examined the
genetic effects in our SLE cohort from a Korean population.
Materials and methods
A total of 593 Korean SLE patients (mean age, 32.36 (6.99–
70.7); male = 35 and female = 558) who fulfilled the 1997
American College of Rheumatology (ACR) criteria for SLE [3]
were consecutively enrolled between September 1998 and
February 2005 at the Hospital for Rheumatic Diseases, Han-
yang University, Seoul, Korea. The following clinical and
ACR = American College of Rheumatology; dbSNP = database of SNP; IFN = interferon; IRF5 = IFN regulatory factor 5; OR = odds ratio; SAS = 
statistical analysis system; SLE = systemic lupus erythematosus; SLICC = Systemic Lupus International Collaborating Clinics; SNP = single nucle-
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laboratory data were obtained: sex, age, ages at onset of first
symptom and clinical diagnosis, ACR diagnosis, and Systemic
Lupus International Collaborating Clinics (SLICC)/ACR dam-
age index [4]. As a control group, we included 971 healthy,
ethnic-matched subjects (mean age, 37.2 (16.6–78.6); male
= 139 and female = 832).
Four SNPs (rs729302 (A > C), rs2004640 (G > T), rs752637
(T > C) and rs2280714 (T > C)) were genotyped, using the
TaqMan® (Applied Biosystems, Foster City, CA, USA) method
[5], in our SLE cases and controls from the Korean population.
Information regarding the primers is available on our website
[6].
χ2 analyses were used to evaluate the significance of differ-
ences in genotype and allele frequencies in the case-control
samples using Statistical Analysis System (SAS). The allele
frequencies for cases and controls were used to calculate the
odds ratio (OR) and the 95% confidence interval using SAS.
For the case-control haplotype analysis, Haploview v3.2
(Broad Institute of Harvard and MIT Cambridge, MA, USA)
was used to generate haplotype frequencies and calculate the
significance of associations. The Breslow–Day statistic was
used to test for homogeneity among studies. A Mantel–Haen-
szel meta-analysis was performed on the ORs, and these data
were subsequently combined in a separate analysis with the
published results of the association of rs2004640 (G > T)
with SLE from previous studies [1,2]. Further conditional anal-
yses and global haplotype tests were performed using WHAP
software [7] developed by Shaun Purcell (Massachusetts
General Hospital, Boston, MA, USA) and Pak Sham (Hong
Kong University, Hong Kong). This analysis was used to disen-
tangle the correlation structure in the gene, to rule out the pos-
sibility that multiple observed effects are owing to linkage
disequilibrium from a single true effect.
Results and discussion
Genotype distributions of all loci were in Hardy–Weinberg
equilibrium (P > 0.05). The frequency of the rs2004640 T
allele, which has a central role in IRF5 polymorphisms, was
significantly lower in the Korean population (frequency, 0.345)
than white populations (frequency, 0.570; Table S2 in Addi-
tional file 1).
Statistical analysis revealed the results in the Korean popula-
tion were similar to the previous reports from white popula-
tions [1,2]. The rs2004640 T allele was significantly
associated with an increased risk of SLE (Table 1), for example
it had a higher frequency in SLE cases (0.385) than controls
(0.321; OR = 1.32, P  = 0.0003). The two nearby SNPs
(rs729302 and rs752637) that were strongly linked to
rs2004640 (|D'| = 0.83 and 0.98, respectively; Figure S1 in
Additional file 1) and the haplotype (rs2004640T–
rs2280714T) that was associated with both the alternative
splice donor site and elevated levels of expression of IRF5 [1]
were also significantly associated with SLE (Table 1 and Table
S1 in Additional file 1).
The observation that the presence of risk haplotypes within
datasets can create spurious protective effects for other hap-
lotypes lead us to perform the same global test conditioning
for the predisposing haplotype (T–T). Conditioning for the pre-
disposing haplotype (T–T) revealed that no significant haplo-
typic association remained in the dataset (χ2 (2 degrees of
freedom) = 5.456, P = 0.07). These results might suggest that
the risk haplotype (T–T) could explain the total association, for
example the protective effect of the haplotype (G–T) was not
real and could be just a shadow effect of the risk haplotype (T–
T).
In combined analysis, including all eight independent cohorts
(Finland, Iceland, USA, Spain, Sweden-1, Sweden-2, Argen-
tina and Korea) from the three studies so far, robust and con-
sistent associations of the rs2004640 T allele with SLE were
observed (Table 2). The Breslow–Day test for heterogeneity
was not significant for allele distributions (P = 0.7115, data
not shown), suggesting the homogeneity of studies. The esti-
mate of risk was OR = 1.44 (1.34–1.55), with an overall P =
1.85 × 10-23 for the rs2004640 T allele (Table 2). The haplo-
type (rs2004640T–rs2280714T) involved in both the alterna-
tive splice donor site and the elevated levels of expression of
IRF5 [1] also had a highly significant association with SLE
(pooled, P = 2.11 × 10-16; Table S1 in Additional file 1). The
strengths of the associations of both the rs2004640 T allele
and the haplotype were high enough to surpass the correction
for multiple testing, even with all of the variants in the human
genome.
Genetic association studies provide a potentially powerful tool
for identifying genetic variations that influence susceptibility to
common diseases. However, there are numerous cases of
associations that cannot be replicated afterwards, which have
led to skepticism about genetic epidemiology studies of com-
plex diseases [8-10]. To discourage false-positive association
hypotheses, several recommendations have been suggested:
large sample sizes, small P values, a gene/allele with biologi-
cally/physiologically meaningful sense, an association
observed in both family- and population-based studies, repli-
cations in independent studies, and a high OR and/or attribut-
able risk [8]. Among these criteria, validation of a genetic
association by replication might be the most important step to
exclude false-positive associations. In statistical terms, inde-
pendent replication decreases the chances of reporting an
association if no association actually exists (type I error). In the
case of association of the IRF5 variant with SLE, which has
satisfied most of the above criteria and been replicated among
numerous white populations, additional replications among
separate sets of patients with different ethnic backgrounds,
such as African and/or Asian populations, would strengthen
the confidence in any association study and allow significantAvailable online http://arthritis-research.com/content/9/2/R32
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gains in narrowing the disease associated interval owing to dif-
ferent patterns of linkage disequilibrium. In this study of a
Korean SLE cohort, we present associations of IRF5 variants
with SLE similar to those suggested by previous studies.
Transcription factors of the IRF family have essential roles in
the regulation of genes induced by viral infection and immu-
nostimulation, in addition to regulation of cell growth. IRF5 was
originally identified as a regulator of type I IFN gene expression
[11]. IRF5 is regulated by type I IFN, indicating an important
regulatory pathway for the controlled induction of multiple
immunomodulatory genes. The constitutive expression of IRF5
is limited to lymphoid organs, dendritic cells and peripheral
blood lymphocytes; however, it is absent in numerous leukae-
mia and lymphoma cell lines [11], which might indicate a pro-
pensity for IRF5  gene deletion or possibly silencing by
methylation in these malignancies [11]. IRF5 is phosphor-
ylated in cells on viral infection and translocates to the nucleus,
which results in activation of a spectrum of IFN genes [11].
Thus, polymorphism within the IRF5 gene might affect several
cellular functions of importance for the development of an
autoimmune disease, such as SLE. The rs2004640 T allele
creates a 5' donor splice site in an alternate exon 1 of IRF5 and
might thus have a functional role by altering the splicing of
exon 1 of the IRF5 [2].
Conclusion
Association analysis of IRF5 polymorphisms revealed that the
results in the Korean population were similar to those in the
previous reports from white populations, for example the
Table 1
Allele/haplotype distribution of IRF5 polymorphisms in Korean SLE patients/controls and association analysis for SLE
Loci Associated allele Cases Controls OR (95% CI) χ2 Pa
(n = 593) (n = 972)
rs729302 (A > C) A 0.729 0.680 1.27 (1.08–1.49) 8.44 0.0037
rs2004640 (G > T) T 0.385 0.321 1.32 (1.14–1.54) 13.22 0.0003
rs752637 (T > C) C 0.455 0.398 1.27 (1.09–1.47) 9.73 0.0018
rs2280714 (T > C) T 0.395 0.402 0.97 (0.84–1.13) 0.15 0.6971
Haplotypeb AGTC 0.355 0.368 0.95 (0.82–1.11) 0.49 0.4840
ATCT 0.352 0.295 1.28 (0.10–1.50) 10.85 0.001
CGTT 0.158 0.205 0.74 (0.61–0.89) 10.21 0.0014
CGCT 0.066 0.071 0.96 (0.72–1.28) 0.34 0.5600
CGTC 0.034 0.024 0.97 (0.63–1.50) 0.78 0.3784
CTCT 0.016 0.017 1.23 (0.72–2.09) 0.07 0.7919
Haplotypec T–T 0.380 0.311 1.36 (1.16–1.58) 15.2 9.64 × 10-5
G–T 0.225 0.283 0.74 (0.62–0.87) 12.5 0.0004
G–C 0.387 0.398 0.95 (0.82–1.11) 0.4 0.5330
T–T 0.008 0.008 0.96 (0.42–2.21) 0.0 0.9323
Case-control analysis. χ2 analyses were used to evaluate the significance of differences in genotype and allele frequencies in the case-control 
samples. The allele frequencies for cases and controls were used to calculate the OR and the 95% CI. For the case-control haplotype analysis, 
Haploview v3.2 (Broad Institute of Harvard and MIT Cambridge, MA, USA) was used to generate haplotype frequencies and calculate the 
significance of associations. CI, confidence interval; IRF5, IFN regulatory factor 5; OR, odds ratio; SLE, systemic lupus erythematosus.
aP value, uncorrected for multiple tests.
bHaplotype consisting of markers rs729302 (A > C), rs2004640 (G > T), rs752637 (T > C) and rs2280714 (T > C).
cHaplotype consisting of markers rs2004640 (G > T) and rs2280714 (T > C).Arthritis Research & Therapy    Vol 9 No 2    Shin et al.
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rs2004640 T allele of IRF5 revealed a susceptible effect on
the risk of SLE. These results indicate that the genetic effect
on the risk of SLE mediated by IRF5 variants could be gener-
ally accepted in both white and Asian populations.
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Table 2
Case-control association analysis of the IRF5 rs2004640 (G > T) T allele with SLE
n No. of T 
alleles
Frequency 
of T alleles
No. of G 
alleles
Frequency of 
G alleles
OR (95% CI) Pa Pooled ORb Pooled Pb
Korea Cases 589 454 0.385 724 0.615 1.32 (1.14–1.54) 0.0003
Controls 950 610 0.321 1290 0.679
Argentinac Cases 284 309 0.54 259 0.46 1.52 (1.20–1.93) 0.00035
Controls 279 245 0.44 313 0.56
Spainc Cases 444 559 0.63 329 0.37 1.42 (1.18–1.71) 0.00016
Controls 541 589 0.54 493 0.46
1.45 (1.32–1.58) 4.4 × 10-16
Sweden-1c Cases 208 260 0.63 156 0.38 1.31 (1.01–1.71) 0.04268
Controls 254 284 0.56 224 0.44
USAc Cases 725 879 0.61 571 0.39 1.47 (1.29–1.67) 3.6 × 10-9
Controls 1,434 1,467 0.51 1401 0.49
Sweden-2d Cases 480 595 0.62 365 0.38 1.51 (1.21–1.87) 0.0002
Controls 256 266 0.52 246 0.48
1.59 (1.31–1.94) 7.1 × 10-7
Finlandd Cases 109 137 0.63 81 0.37 1.84 (1.27–2.66) 0.00133
Controls 121 116 0.48 126 0.52
Combined analysis Cases 2,839 3,193 0.56 2,485 0.44 1.44 (1.34–1.55) 1.85 × 10-23
Controls 3,835 3,577 0.47 4,093 0.53
Meta-analysis. Mantel–Haenszel meta-analysis of the ORs; these data were subsequently combined in a separate analysis with the published 
results of the association of rs2004640 (G > T) with SLE from previous studies [1,2]. The Breslow–Day test for heterogeneity was not significant 
for allele distributions (P = 0.7115, data not shown), suggesting the homogeneity of studies. 'Number of alleles' refers to number of alleles of 
rs2004640 (G > T). CI, confidence interval; IRF5, IFN regulatory factor 5; OR, odds ratio; SLE, systemic lupus erythematosus.
aχ2 tests were used to evaluate the significance of differences in allele frequencies in the case-control samples.
bMantel–Haenszel test [12] of pooled ORs and 95% CIs.
cData from Graham and co-workers [1].
dData from Sigurdsson and co-workers [2].Available online http://arthritis-research.com/content/9/2/R32
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